Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email mava@mava.org.
 

 

Check back regularly for news, coverage, and announcements about MAVA.

  

Epidarex unveils £50m venture capital fund for UK life sciences

05/28/2014

Investors keen to capitalise on British science have poured nearly £50m into a new venture capital fund.

Epidarex, a specialist life science venture capital group, will on Thursday unveil a new £47.5m fund dedicated to
UK start-ups, including university spin-outs.

Backers include
US drug giant Eli Lilly as well as King’s College London and other major research universities. It has also attracted investment from the EU’s European Investment Fund, Scottish Enterprise and Strathclyde Pension Fund.

Elaine Sullivan, vice-president of global external research and development at Lilly, said the
US drugmaker’s investment, its first in a UK venture capital fund, underlined its belief in Britain as a scientific powerhouse.

“This investment reflects Lilly’s strong belief in the excellence of life science research and development in the
UK and will complement our own R&D and existing academic partnerships,” she said.

Learn More